Becker Capital Management Inc. Has $41.04 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Becker Capital Management Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 254,120 shares of the company’s stock after acquiring an additional 6,196 shares during the quarter. Johnson & Johnson accounts for 1.7% of Becker Capital Management Inc.’s portfolio, making the stock its 10th largest position. Becker Capital Management Inc.’s holdings in Johnson & Johnson were worth $41,040,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in JNJ. Clarius Group LLC increased its position in Johnson & Johnson by 3.5% in the second quarter. Clarius Group LLC now owns 27,970 shares of the company’s stock worth $4,608,000 after purchasing an additional 934 shares during the period. Eukles Asset Management boosted its holdings in Johnson & Johnson by 17.6% during the second quarter. Eukles Asset Management now owns 10,601 shares of the company’s stock worth $1,746,000 after buying an additional 1,587 shares during the last quarter. Cooke & Bieler LP boosted its holdings in Johnson & Johnson by 3.9% during the second quarter. Cooke & Bieler LP now owns 744,378 shares of the company’s stock worth $122,629,000 after buying an additional 28,195 shares during the last quarter. EFG Asset Management Americas Corp. boosted its holdings in Johnson & Johnson by 12.3% during the second quarter. EFG Asset Management Americas Corp. now owns 9,832 shares of the company’s stock worth $1,620,000 after buying an additional 1,075 shares during the last quarter. Finally, Pallas Capital Advisors LLC boosted its holdings in Johnson & Johnson by 16.7% during the second quarter. Pallas Capital Advisors LLC now owns 48,435 shares of the company’s stock worth $8,397,000 after buying an additional 6,920 shares during the last quarter. Hedge funds and other institutional investors own 67.14% of the company’s stock.

A number of equities analysts have issued reports on the company. Wells Fargo & Company restated a “buy” rating on shares of Johnson & Johnson in a report on Thursday, October 7th. SVB Leerink restated a “buy” rating on shares of Johnson & Johnson in a report on Thursday, July 29th. Raymond James reduced their target price on Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, October 20th. Morgan Stanley cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective on the stock. in a report on Tuesday, September 7th. Finally, Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 price objective on the stock in a report on Friday, October 22nd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $187.78.

Johnson & Johnson stock traded down $0.45 during midday trading on Thursday, reaching $160.24. The stock had a trading volume of 5,230,043 shares, compared to its average volume of 7,039,470. The firm’s fifty day simple moving average is $162.64 and its 200-day simple moving average is $167.35. Johnson & Johnson has a 1-year low of $142.86 and a 1-year high of $179.92. The stock has a market capitalization of $421.85 billion, a P/E ratio of 23.95, a price-to-earnings-growth ratio of 2.38 and a beta of 0.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.11 and a current ratio of 1.34.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Monday, October 18th. The company reported $2.60 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.35 by $0.25. Johnson & Johnson had a return on equity of 37.90% and a net margin of 19.55%. The business had revenue of $23.34 billion for the quarter, compared to analyst estimates of $23.72 billion. During the same quarter last year, the firm earned $2.20 EPS. Johnson & Johnson’s revenue for the quarter was up 10.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.78 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 7th. Investors of record on Tuesday, November 23rd will be given a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a yield of 2.65%. The ex-dividend date is Monday, November 22nd. Johnson & Johnson’s dividend payout ratio is presently 63.38%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Story: Tariff

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.